Jeyanthi Ramanarayanan, MD

Specialties:
Hematology/Medical Oncology
Department:
Adena Cancer Center
Phone Number:
(740) 542-3030
Fax Number:
(740) 542-7871
This physician is available for online scheduling. Request an Appointment

Additional Information

Medical School
Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India, Doctor of Medicine
Internship
Mount Sinai School of Medicine, Jersey City, NJ
Residency
Mount Sinai School of Medicine, Jersey City, NJ
Fellowships
Clinical Fellowship in Oncology, Roswell Park Cancer Institute, Buffalo, NY, Clinical Fellowship in Hematology, University at Buffalo at Erie County Medical Center, Buffalo, NY
Professional Memberships
American Society of Clinical Oncology, American Society of Hematology, American Association of Physicians of Indian Origin, Blood Bank Association of New York
Publications
1. Tamascar I, Ramanarayanan J: Targeted treatment of chronic myeloid leukemia: role of imatinib. Onco Targets and Therapy, 2009. 2. Ramanarayanan J, Krishnan GS: Review: hepatotoxicity and EGFR inhibition. Clin Adv Hematol Oncol 6(3):200-201, 2008 Mar. PMID 18391919 3. Krishnan GS, Chaudhary V, Al-Janadi A, Ramanarayanan J, D’Silva KJ: BCNU toxicity presenting with a large pericardial and pleural effusion. Ann Transplant 13(1):44-7, 2008. PMID 18344943 4. Ramanarayanan J, Scarpace SL: Acute drug induced hepatitis due to erlotinib. JOP 8(1):39-43; 2007 Jan 9. PMID: 17228132 5. Ramanarayanan J, Brodzik F, Mehdi S, Pasquale D: Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib. Hematology. 20:1 [Epub ahead of print] 2007 Jun. PMID: 17852464 6. Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Maria Baer, Lawrence W, McCarthy PL: Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients. Leuk Res. 2005 Dec 2. PMID: 16330096 7. Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS: Pro-apoptotic therapy with the oligonucleotide Genasense™ (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumor activity of rituximab. Br J Haematol. 127(5):519-30, 2004 Dec. PMID: 15566355. 8. Winston JS, Ramanarayanan J, Levine E: HER2/neu evaluation in Breast Cancer: Are we there yet? Am J Clin Pathol 121 Suppl: S33-49, 2004 Jun. PMID 15298149 9. Ramanarayanan J, Krishnan G, Hernandez-Ilizaliturri F: Factor VII. Hematology/Internal Medicine. E-medicine Journal. 10. Rencic A, Ramanarayanan J: Leukemia Cutis. Dermatology, Internal Medicine Section in E- medicine Journal.
Gender
Female

About

Learn more about cancer care and the Adena Cancer Center.